Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Recombinant
100%
α-galactosidase
100%
Male Patients
100%
Fabry Disease
100%
Anti-drug Antibodies
100%
Antibody Development
42%
ROC-AUC
28%
Logistic Regression Model
28%
Enzyme Replacement Therapy
28%
Fabry Disease Patient
28%
Prediction Model
14%
Random Forest Regression
14%
Treatment Initiation
14%
Cerebral Complications
14%
Renal Complications
14%
European Centre
14%
Immunization
14%
Cardiac Complications
14%
LysoGb3
14%
Frameshift mutation
14%
Treatment Prediction
14%
X-linked
14%
β-Galactosidase (β-Gal)
14%
First Treatment
14%
Performance Prediction
14%
Existing Data
14%
Development Risk
14%
Renal Function
14%
Agalsidase-β
14%
Nonsense mutation
14%
Immunomodulatory
14%
Biochemical Response
14%
Toleration
14%
Lysosomal Storage Disease
14%
Medicine and Dentistry
Fabry Disease
100%
Drug Antibody
100%
Alpha-Galactosidase
100%
Enzyme Replacement Therapy
28%
Logistic Regression Analysis
28%
Frameshift Mutation
14%
Kidney Function
14%
Galactosidase
14%
Agalsidase Beta
14%
Nonsense Mutation
14%
Lysosomal Storage Disease
14%
Biochemistry, Genetics and Molecular Biology
Fabry Disease
100%
Monospecific Antibody
100%
Alpha-Galactosidase
100%
Enzyme
28%
Frameshift Mutation
14%
Nonsense Mutation
14%
Lysosomal Storage Disease
14%
Galactosidase
14%
Kidney Function
14%
Random Forest
14%
Pharmacology, Toxicology and Pharmaceutical Science
Drug Antibody
100%
Alpha Galactosidase
100%
Fabry Disease
100%
Replacement Therapy
28%
Agalsidase Beta
14%
Lysosome Storage Disease
14%
Galactosidase
14%
Neuroscience
Alpha Galactosidase
100%
Drug Antibody
100%
Enzyme Replacement Therapy
28%
Nonsense Mutation
14%
Agalsidase Beta
14%
Galactosidase
14%
Frameshift Mutation
14%